Spencer Guthrie

Spencer brings deep strategic and operational expertise with 24 years in drug development and commercialization in both large and small biotech. He has dedicated more than 13 years of his career to amyloid-related diseases, including AL and ATTR amyloidosis, Alzheimer’s and Parkinson's disease, and has authored over 30 scientific publications in amyloidosis.

Prior to founding Attralus, he was VP, Head of Global Strategy at Akcea and Ionis, and responsible for the ATTR franchise strategy. Prior to that, he was VP, Head of Development Operations and Medical Affairs for Prothena Biosciences leading programs in AL and ATTR Amyloidosis. In addition, Spencer has significant leadership experience in clinical development, portfolio program management and commercial operations at Genentech, Elan, Janssen and Ultragenyx contributing to bring numerous therapeutic candidates from development to patients in need, including Avastin®, Rituxan®, Lucentis®, Tysabri®, Crysvita®, Mepsevii®, and Dojolvi®.

Spencer received a BS in Neuroscience from Vanderbilt University, and an MBA from the Paul Merage School of Business at the University of California.